GGrantIndex
Sort

11,323 grants matching glioblastoma

Intedrated Imagaing and Tissue Biomarkers in Glioblastoma Multiforme Post Therapy

$223,194
Susan M Chang · University Of California, San Francisco · P01 · FY2009 · CA

Lactate Transport as a Therapeutic Target in Glioma

$223,009
Saroj Priyantha Mathupala · Wayne State University · R01 · FY2007 · CA

Microvesicles as potential genetic biomarkers of brain tumors

$222,971
Xandra Owens Breakefield · Massachusetts General Hospital · P01 · FY2012 · CA

TEMODAR RESISTANCE IN CENTRAL NERVOUS SYSTEM

$222,962
Henry S. Friedman · Duke University · P50 · FY2007 · CA

Project 4-Monika Rak

$222,838
Monika Rak · Lsu Health Sciences Center · P20 · FY2025 · GM

Dysregulation of mTORC2 in gliomas

$222,812
Joseph F Gera · Brentwood Biomedical Research Institute · R01 · FY2014 · CA

Using artificial intelligence and MRI to address limitations in glioblastoma

$222,751
Andra Krauze · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Proteogenomic characterization and biomarker discovery in glioblastoma

$222,751
Andra Krauze · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Prognostic and predictive clinical and proteomic biomarker discovery in GBM

$222,751
Andra Krauze · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Modeling low-grade gliomas using human pluripotent stem cells

$222,750
Rui Zhao · University Of Alabama At Birmingham · R21 · FY2019 · NS

Highly multiplexed live-cell GPCR arrays for drug discovery in glioma.

$222,717
Jonathan W Jarvik · Spectragenetics · R41 · FY2021 · CA

Targeting the PI3K Pathway in Malignant Glioma

$222,389
W K Alfred Yung · University Of Tx Md Anderson Can Ctr · P50 · FY2014 · CA

A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS

$222,359
John Anthony Muraski · Endurx Pharmaceuticals, Inc. · R44 · FY2014 · CA

A20 Promotes Glioma Stem Cell Mediated Tumorigenesis

$222,309
Anita Borton Hjelmeland · University Of Alabama At Birmingham · R01 · FY2013 · CA

Development of Parametric Response Mapping Software for Clinical Cancer Response Assessment

$222,255
Lauren Keith · Imbio, Llc · R44 · FY2016 · CA

EGFR MUTATIONS IN MALIGNANT GLIOMAS

$222,233
Mayo Clinic Coll Of Medicine, Rochester · R01 · FY2001 · CA

EGFR MUTATIONS IN MALIGNANT GLIOMAS

$222,233
Mayo Clinic Coll Of Medicine, Rochester · R01 · FY2000 · CA

Dual responsive nanoparticle for brain targeted drug delivery

$222,223
Peisheng Xu · University Of South Carolina At Columbia · P20 · FY2017 · GM

AI-Based Modeling and Drug Development

$222,049
Wei Zheng · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR

A new kinase inhibitor for glioblastoma

$221,850
Raymond Daniel Blind · Vanderbilt University Medical Center · R21 · FY2019 · CA

Role of LAP positive immune cells in glioblastoma pathogenesis

$221,823
Howard L Weiner · Brigham And Women'S Hospital · R21 · FY2015 · NS

Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer

$221,727
Neeha Zaidi · Johns Hopkins University · K08 · FY2022 · CA

Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer

$221,727
Neeha Zaidi · Johns Hopkins University · K08 · FY2024 · CA

Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer

$221,727
Neeha Zaidi · Johns Hopkins University · K08 · FY2021 · CA

Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer

$221,727
Neeha Zaidi · Johns Hopkins University · K08 · FY2023 · CA